Development of a Bacillus subtilis -Based Rotavirus Vaccine
Open Access
- 1 November 2010
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (11) , 1647-1655
Abstract
Bacillus subtilis vaccine strains engineered to express either group A bovine or murine rotavirus VP6 were tested in adult mice for their ability to induce immune responses and provide protection against rotavirus challenge. Mice were inoculated intranasally with spores or vegetative cells of the recombinant strains of B. subtilis . To enhance mucosal immunity, whole cholera toxin (CT) or a mutant form (R192G) of Escherichia coli heat-labile toxin (mLT) were included as adjuvants. To evaluate vaccine efficacy, the immunized mice were challenged orally with EDIM EW murine rotavirus and monitored daily for 7 days for virus shedding in feces. Mice immunized with either VP6 spore or VP6 vegetative cell vaccines raised serum anti-VP6 IgG enzyme-linked immunosorbent assay (ELISA) titers, whereas only the VP6 spore vaccines generated fecal anti-VP6 IgA ELISA titers. Mice in groups that were immunized with VP6 spore vaccines plus CT or mLT showed significant reductions in virus shedding, whereas the groups of mice immunized with VP6 vegetative cell vaccines showed no difference in virus shedding compared with mice immunized with control spores or cells. These results demonstrate that intranasal inoculation with B. subtilis spore-based rotavirus vaccines is effective in generating protective immunity against rotavirus challenge in mice.Keywords
This publication has 62 references indexed in Scilit:
- Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile ToxinPLOS ONE, 2009
- A Dose‐Escalation Safety and Immunogenicity Study of Live Attenuated Oral Rotavirus Vaccine 116E in Infants: A Randomized, Double‐Blind, Placebo‐Controlled TrialThe Journal of Infectious Diseases, 2009
- Rotavirus Vaccines — Early Success, Remaining QuestionsNew England Journal of Medicine, 2009
- Intranasal bacteria induce Th1 but not Treg or Th2Mucosal Immunology, 2008
- Rotavirus Vaccines: an OverviewClinical Microbiology Reviews, 2008
- Rotavirus Anti-VP6 Secretory Immunoglobulin A Contributes to Protection via Intracellular Neutralization but Not via Immune ExclusionJournal of Virology, 2006
- Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: Results of a randomised controlled trialVaccine, 2006
- Mucosal Immune Responses and Protection against Tetanus Toxin after Intranasal Immunization with RecombinantLactobacillus plantarumInfection and Immunity, 2001
- Differential production of IL-12 in BALB/c and DBA/2 mice controls IL-4 versus IFN-γ synthesis in primed CD4 lymphocytesInternational Immunology, 1996
- Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mpl8 and pUC19 vectorsGene, 1985